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Abstract Since many drugs are cytochrome P450 (CYP)-
3A4 substrates, it has become common practice to assess
drug–drug interaction (DDI) potential with a CYP3A4
inhibitor (ketoconazole) or inducer (rifampicin) in early
drug development. Such an evaluation is relevant to anti-
cancer drugs with metabolism governed by CYP3A4. DDIs
with rifampicin are complex, involving other physiological
mechanisms that may impact overall pharmacokinetics.
Our objective was to study and delineate such mechanisms
for oral versus intravenous anticancer drugs. We hypothe-
sized that DDIs between anticancer drugs and rifampicin
were primarily driven by CYP3A4 induction. This
hypothesis was proven for the oral anticancer drugs;
however, in some cases, other intrinsic mechanisms such as
P-glycoprotein (Pgp)/UDP glucuronosyl transferase (UGT)
induction and transporter inhibition may have played an
important role alongside the induced CYP3A4 enzymes.
The hypothesis that CYP3A4 induction would decrease
drug exposure appeared paradoxical for intravenous romi-
depsin and—to a somewhat lesser extent—for cabazitaxel.
In light of this dilemma in the interpretation of the phar-
macokinetic data with rifampicin, several questions require
further consideration. Given the complexity and paradox-
ical effects arising with DDIs with rifampicin, the contin-
ued preference for rifampicin as CYP3A4 inducer needs
immediate re-appraisal.
Key Points
Rifampicin is the preferred probe to facilitate
cytochrome P450 (CYP)-3A4 induction in drug–
drug interaction studies involving drugs metabolized
via the CYP3A4 enzyme.
Since rifampicin can affect other physiological
processes besides CYP3A4 induction, it may lead to
paradoxical observations as illustrated by the data
gathered for oral versus intravenous anticancer
drugs.
In light of the complexity and challenges involved in
data interpretation, the continued dependency on the
preference of rifampicin as an CYP3A4 inducer
needs immediate re-appraisal.
1 Introduction
A majority of drugs undergo metabolism via cytochrome
P450 (CYP) enzymes, particularly CYP3A4 [1, 2].
Therefore, in early drug development, greater importance
has been given to evaluation of the potential for drug–drug
interactions (DDIs) due to inhibition and induction of
CYP3A4. This aspect is particularly relevant to many
anticancer drugs whose metabolic disposition is governed
by CYP3A4 [3–8]. Whereas CYP3A4 inhibition may
inadvertently increase exposure to the drug beyond the safe
therapeutic index, CYP3A4 induction may drastically
reduce the exposure, resulting in possible efficacy failure.
Ketoconazole and rifampicin are the standard probe sub-
strates used for, respectively, inhibition and induction of
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CYP3A4 in clinical protocols to assess the potential for
DDIs.
DDIs with ketoconazole are understood and predictable;
however, DDIs with rifampicin have always remained
complex because rifampicin is involved to various degrees
in the physiological processes that govern absorption,
metabolism, distribution (uptake transporters), and excre-
tion (efflux transporters and biliary excretion) of the co-
administered drugs [9–19], as depicted in Fig. 1.
Rifampicin is rapidly absorbed in humans, generally
within 2 h, with an approximate peak concentration (Cmax)
of 10 lg/ml after a standard single oral dose of 600 mg
[19]. It has been suggested that higher doses of rifampicin
may saturate the metabolism and liver uptake of rifampi-
cin, which may result in a disproportionate increase in
rifampicin plasma levels [19]. The main metabolite of
rifampicin is formed via a deacetylation process in the liver
to form desacetylrifampicin, which has been found to be an
active metabolite in the antimicrobial activity of the drug.
The elimination half-life of rifampicin is 2.5 h, and the
mass balance suggests that rifampicin is excreted almost
equally between renal and fecal routes. Upon repeated
administration, rifampicin showed lower Cmax and area
under the concentration–time curve (AUC) values because
of auto-induction of its own metabolism via CYP3A4
isozymes [19]. Further, the disposition of rifampicin is
governed by sinusoidal efflux transporters for biliary
excretion [13, 16, 17] as well as for the formation of the
glucuronide conjugate of the desacetylrifampicin, which is
also excreted via biliary mechanisms [19].
As shown in Table 1, the main mechanism for DDIs
with rifampicin is via the induction CYP3A4 enzyme, with
the exception of cediranib where UGT induction was the
likely perpetrator. Although rifampicin is used primarily
for its ability to induce CYP3A4, its other effects also
affect the overall pharmacokinetics of co-administered
drugs. In this report, we cite recently published pharma-
cokinetic data for anticancer drugs such as cabazitaxel,
navitoclax, cabozantinib, cediranib, idelalisib, and romi-
depsin [3–8] to highlight the dilemma with using rifampi-
cin, which is that the potential for DDIs may be
paradoxical in nature and unexpected in some situations.
Since polypharmacy is increasingly common, the assimi-
lation and systematic evaluation of such pharmacokinetic
interaction data will improve understanding when different
mechanisms come into play.
2 Drug–Drug Interactions (DDIs) with Oral
Anticancer Drugs
Table 1 provides the pharmacokinetic interaction data for
navitoclax, cabozantinib, idelalisib, and cediranib when co-
administered with rifampicin. In three examples, the
mechanism was via the induction of CYP3A4 and in one
case it was with the induction of UGT.
METABOLISM 
Eﬄux via P-glycoprotein (Pgp) 
inducon [9] 
Eﬀect(s) on 
parent drug Mechanism(s) 
Decreased drug exposure 
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 Inhibion of uptake 
transporters (OATP1B1; 
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sinusoidal/cannalicular eﬄux  
transporter (MRP1/2, BCRP, 
[13,16,17] 
Inhibion of bile acid 
transporters – NTCP, BSEP [18] 
Compeon with passive 
biliary excreon [19] 
Increased parent drug exposure 
Enhanced oral bioavailability 
Decreased clearance (due to 
enzymac saturaon) 
Direct compeon with 
glucuronidaon pathway [19] 
Increased parent drug exposure 
Physiological 
process 
Fig. 1 Possible areas for
potential clinical drug–drug
interaction between rifampicin
and the co-administered drugs
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2.1 Navitoclax
Navitoclax represents a novel first-in-class small-molecule
drug that has a high inhibitory affinity to the Bcl-2 family
of receptors [20]. Although the disposition of navitoclax is
governed predominantly by hepatic metabolism via
CYP3A4 in non-clinical species [3], the human pharma-
cokinetic data suggested a moderate effect on the clearance
of navitoclax when co-administered with rifampicin
(Table 1). Earlier data suggested that navitoclax was a
substrate for P-glycoprotein (Pgp) [21]. However, since the
Cmax values of navitoclax were comparable between pre-
and post-rifampicin treatment phases, and rifampicin pre-
treatment moderately increased the clearance of navitoclax
[3], it may be safely concluded that Pgp may possibly play
a minor role in the disposition of navitoclax.
2.2 Cabozantinib
Cabozantinib is a tyrosine kinase inhibitor with modula-
tions of vascular endothelial growth factor receptor 2 and
hepatocyte growth factor receptor [22]. The in vitro
metabolism study demonstrated that CYP3A4 was the main
CYP enzyme responsible for the N-oxidation of cabozan-
tinib, and inhibition of the CYP3A4 pathway resulted in a
[80 % reduction in the formation of N-oxide metabolite
[23]. Given the predominant role of CYP3A4 in the
metabolism of cabozantinib [4], pre-treatment with rifam-
picin showed a profound increase in the clearance of
cabozantinib (Table 1). Interestingly, although cabozan-
tinib was also found to be a substrate for several trans-
porters, such as OATP1B1, OATP1B3, and MRP2 [24],
rifampicin treatment appeared to have no bearing on these
transporters as judged by the clearance of cabozantinib [4].
Additionally, since cabozantinib was also a substrate for
Pgp [24], this may also have contributed to the observed
higher clearance of the drug during rifampicin treatment
[4].
2.3 Idelalisib
Idelalisib is a small-molecule drug with high selectivity
and affinity for the competitive inhibition of adenosine-50-
triphosphate binding to the catalytic subunit of the phos-
phoinositide 3-kinase (PI3K)-d enzyme; the inhibition of
PI3Kd-Akt signaling resulted in reduced proliferation and
induction of apoptosis [25, 26]. The role of CYP3A4 in the
oxidative metabolism of idelalisib was minor because
aldehyde oxidase primarily catalyzed the formation of the
major metabolite GS-563117, which was devoid of phar-
macological activity [5]. Interestingly, idelalisib was noted
to be an inhibitor of Pgp, OATP1B1, and OATP1B3,
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time-dependent CYP3A4 inhibitor [5]. The inclusion of
probe substrates such as digoxin (Pgp) and rosuvastatin
(OATP1B1 and OATP1B3) confirmed the lack of any
clinically meaningful pharmacokinetic interaction of ide-
lalisib upon co-administration of the two drugs [5]. The
lack of significant change in the midazolam (CYP3A4
probe) pharmacokinetics upon co-administration with ide-
lalisib refuted the notion that GS-563117 was a time-de-
pendent CYP3A4 inhibitor [5]. In combination, the above
key observations suggest the interaction of idelalisib with
rifampicin would not be influenced by other competing
mechanisms, with the exception of CYP3A4. Because
CYP3A4 is a minor enzyme responsible for the conversion
of idelalisib to GS-563117, it was thought that CYP3A4
induction may lead to a moderate increase in the clearance
of idelalisib. However, the pharmacokinetic data suggest a
profound effect on the clearance of idelalisib (Table 1).
Therefore, it may be speculated that such an observed
effect on the clearance of idelalisib may be only substan-
tiated by induction of the UGT1A4 enzyme and/or Pgp.
Because the exposure of GS-563117 profoundly decreased
[5], it appeared that Pgp induction may have a greater
contribution in explaining the lower bioavailability of both
idelalisib and GS-563117 when co-administered with
rifampicin.
2.4 Cediranib
Cediranib is a highly potent inhibitor of all three subtypes
of vascular endothelial growth factors, resulting in signif-
icant disruption in tumor angiogenesis and growth inhibi-
tion [27, 28]. In vitro studies have confirmed the major
contributor for the metabolism of cediranib was UGT1A4
and flavin-containing monooxygenase, resulting in the
formation of glucuronide metabolite and oxidative
metabolite, respectively [29, 30]. The role of CYP enzymes
in general appeared to be minor in nature. As expected,
pharmacokinetic interaction with rifampicin showed a
modest effect on the decreased exposure or increased
clearance of cediranib, which was consistent with the
induction of UGT1A4 by rifampicin [10–12] (Table 1).
3 DDIs with Intravenous Anticancer Drugs
3.1 Romidepsin
Romidepsin is a novel drug, the anticancer activity of
which is via histone deacetylase (HDAC) inhibitory
mechanisms [31, 32]. The major contributor for the
extensive hepatic metabolism of romidepsin was CYP3A4,
with minor contributions from other CYPs such as 1A1,
2B6, and 2C19 [33]. In a profound paradoxical effect, co-
administration of rifampicin increased exposure and
decreased clearance of romidepsin by an identical value of
approximately 1.8-fold (Table 1). Laille et al. [8] rightly
emphasized the complexity involved in DDIs with rifam-
picin and concluded that inhibition of uptake transporters
may have been responsible for the unexpected surge in the
plasma exposure of romidepsin in cancer patients. How-
ever, Laille et al. [8] opined that, since romidepsin was not
a substrate for either OATP1B1 or OATP1B3, the inhibi-
tion mediated by rifampicin may possibly occur through
inhibition of another as-yet unidentified uptake transporter.
Another important mechanism that may possibly contribute
to the paradoxical phenomenon of rifampicin involves its
effect on the sinusoidal efflux transporter-based biliary
excretion process of drugs and/or direct competition with
phase II glucuronide conjugation pathway followed by
passive biliary excretion (Fig. 1). Although mass balance
data for romidepsin has not been established in human
subjects, romidepsin has been reported to undergo exten-
sive biliary excretion in rats, with almost 80 % of the total
intravenous dose accounted for via the biliary excretory
pathway [8]. Hence, it could be reasonably hypothesized
that continuous daily oral administration of rifampicin in
patients with cancer may have inhibited the MRP-2 trans-
porters, which in turn resulted in a reduced biliary excre-
tion of romidepsin, explaining the high exposure observed
in the DDI study with rifampicin [8]. However, since
romidepsin does not appear to be a substrate for MRP2
[34], it may be speculated that rifampicin may directly
compete with the glucuronidation pathway of romidepsin
and/or passive biliary excretion of romidepsin. It should be
noted that rifampicin undergoes significant phase II meta-
bolism, and an efficient biliary excretion of the parent drug
and metabolites in humans has been observed [19].
3.2 Cabazitaxel
Cabazitaxel is a novel taxane agent recently approved for
the treatment of hormone-refractory metastatic prostate
cancer in combination with either prednisone or pred-
nisolone [32]. The primary metabolic pathway for cabazi-
taxel was governed by the sole enzyme CYP3A4,
contributing to 80–90 % of the total metabolism of the
drug [35]. The pharmacokinetic interaction data with
rifampicin indicated the impact was marginal at best,
suggesting the likelihood of other competing mechanisms
outside of CYP3A4 (Table 1). In this context, Ridoux et al.
[36] recently published the mass balance, disposition, and
excretion data of [14C]cabazitaxel in cancer patients.
Whereas the renal excretion of cabazitaxel was very lim-
ited (approximately 3 %), the major route of elimination of
[14C]cabazitaxel was in the feces (approximately 76 %),
presumably due to predominant biliary excretion of the
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parent drug and the metabolites [36]. Because of its CYP-
related metabolism, several oxidative metabolites were
formed and detected systemically [36], it is therefore
highly likely that phase II metabolism of some of these
oxidative metabolites promote biliary excretion process.
Therefore, in a situation akin to that of romidepsin, pos-
sible inhibition of sinusoidal biliary efflux transporter may
have led to higher levels of cabazitaxel. Also, the direct
competition of UGT enzymes between phase II metabolite
formations for rifampicin versus cabazitaxel may be an
additional contributing factor to explaining the higher
levels of cabazitaxel, which would counter the loss of drug
exposure due to induced CYP3A4 metabolism. In totality,
it appears that the reason why a higher drop in cabazitaxel
was not observed in this study [7] may be due to factors
such as inhibition of biliary efflux transporter and direct
completion with UGT enzymes.
4 Challenges and Perspectives
The few examples of anticancer drugs discussed in this
report demonstrate dilemmas in the interpretation of
pharmacokinetic data after administration of rifampicin.
The hypothesis for the planned DDI studies of the anti-
cancer drugs with rifampicin was primarily driven by the
impact of increased metabolism due to CYP3A4 induction.
However, this hypothesis was proven for the oral anti-
cancer agents, although it appeared that in some cases other
intrinsic mechanisms, such as Pgp induction and/or UGT
induction, may have played an important role alongside the
induced CYP3A4 enzymes. Four important observations
from the oral anticancer drugs that need careful assessment
would be as follows:
1. When CYP3A4 was considered to play a minor role
with idelalisib, the greater than expected decrease in
exposure to idelalisib [5] was a clear reflection of the
important role of the induced Pgp efflux in reducing
the oral bioavailability of idelalisib.
2. When CYP3A4 was considered to play a major role
with navitoclax based on preclinical work in other
species, the observed moderate effect on navitoclax
exposure [3] suggested other mechanisms may enable
the absorption of navitoclax to escape the likely first-
pass effect from the induced CYP3A4. Because
navitoclax has a higher long-chain triglyceride solu-
bility, a preferential lymphatic transport may be
possible, as observed in a canine study [37].
3. In the case of cediranib, although the CYP3A4 enzyme
represented a minor pathway, UGT induction appeared
to be key in explaining the reduced cediranib exposure
[6].
4. The inhibitory role of rifampicin on uptake trans-
porters (OATP1B1 and OATP1B3) and efflux trans-
porter (MRP2) [13–15] did not appear to adversely
affect the clearance of cabozantinib [4], which is an
enigma.
Unfortunately, the hypothesis that CYP3A4 induction
would decrease CYP3A4 substrate exposure appeared
paradoxical for intravenous romidepsin [8] and to a
somewhat lesser extent for cabazitaxel [7]. The dilemma
with intravenous drugs was that they escape the first-pass
metabolism effect of rifampicin as a result induction of
both intestinal CYP3A4 and UGT, along with the induced
Pgp efflux. Hence, the extent of hepatic CYP3A4 and/or
UGT induction may determine the reduced exposure of
intravenous drugs. However, other rifampicin mechanisms
may counter this phenomenon (Fig. 1). The inhibition of
uptake transporters (OATP1B1 and OATP1B3) and bil-
iary sinusoidal efflux transporter (MRP2) by rifampicin
[13–15] may render higher exposure of such anticancer
drugs, which are substrates to any of the above trans-
porters. While romidepsin was not a substrate for any of
them, whether cabazitaxel was a substrate to these
transporters is yet to be established. Nevertheless, it
appeared that potential areas for DDIs between rifampicin
versus romidepsin/cabazitaxel may be due to competitive
passive biliary excretion and/or direct competition with
UGTs for the phase II glucuronide formation. It should be
noted that a high dose of rifampicin was administered for
either 14 days (cabazitaxel) or 5 days (romidepsin), and
because the UGT system is important for the disposition
of rifampicin, UGT depletion over time may become
relevant for both cabazitaxel and romidepsin and possibly
explain the interaction with rifampicin. In this context, a
similar effect—oral drug with profound DDIs with an
intravenous drug acting at the biliary excretion level
(presumably via a passive biliary excretory pathway and/
or interference at the phase II metabolism)—has been
previously demonstrated between cyclosporine and tige-
cycline in transplant patients with infections [38].
Because tigecycline can efficiently compete at the glu-
curonidation pathway and with the biliary excretion of
cyclosporine, it drastically increased the plasma exposure
of the oral cyclosporine, the disposition of which is lar-
gely governed by the biliary excretory pathway [38].
Other processes may have a lower chance of causing an
unexpected outcome in clinical DDI studies with rifam-
picin: protein-binding displacement, influence on the
disposition of the active metabolite(s), and changes to the
intestinal microflora may affect the local absorption and
metabolism/transporter environment.
Given the observed problems with the interpretation of
pharmacokinetic data with rifampicin, several questions
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need to be considered: (1) Should a uniform dosing reg-
imen be considered for DDI studies involving rifampicin
(5 days [n = 1], 7 days [n = 3], 11 days [n = 1], 14 days
[n = 1])? (2) Does rifampicin serve as the right probe to
induce CYP3A4 enzymes for the assessment of pharma-
cokinetics of CYP3A4 substrate drugs? (3) Should
rifampicin be considered a CYP3A4 inducer when intra-
venous drug pharmacokinetics are assessed for CYP3A
drug substrates? (4) Does rifampicin exert similar DDI
potential for the same CYP3A4 drug substrate regardless
of its route of administration? (5) Aside from the above
questions, how should one value the dosing recommen-
dation that arises from the DDI with rifampicin given the
complex interplay due to competing mechanisms? (6)
Does the dosing recommendation, if any, from rifampicin
clinical DDI studies hold good if other CYP3A4 inducers
are ingested during the course of the therapy (e.g., St
John’s Wort)? (7) What should be our level of pre-
paredness with respect to understanding the characteristics
of the drug substrate before we undertake a DDI study
with rifampicin?
5 Conclusions
In summary, paradoxical effects with rifampicin are not
new and have been observed in antiretroviral therapy [39].
Aside from CYP3A4 induction, rifampicin may induce
and/or inhibit other physiological functions that govern
disposition of the drug. Additionally, rifampicin may
directly participate in passive excretory processes and
indirectly participate in depleting enzymes. The paradoxi-
cal effect of rifampicin may differ between oral and
intravenous drugs. Furthermore, it is important to under-
stand the types of enzyme(s) and transporter(s) contributing
to the clearance of the victim drug prior to using rifampicin
as the perpetrator in a planned DDI study, to ensure a
reliable prediction on the magnitude of clinical DDI. While
the DDI study is planned for an induction phenomenon of
CYP3A4 by rifampicin, the repeated rifampicin adminis-
tration may make it more conducive for a potent transporter
inhibition. Therefore, the continued preference for rifam-
picin as the CYP3A4 inducer needs immediate re-
appraisal.
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